Parkman Healthcare Partners LLC Castle Biosciences Inc Transaction History

Parkman Healthcare Partners LLC

$687 Million
Q4 2024

A detailed history of Parkman Healthcare Partners LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 304,629 shares of CSTL stock, worth $6.49 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares

304,629

Previous 296,071 2.89%

Holding current value

$6.49 Million

Previous $8.44 Million 3.85%

% of portfolio

1.18%

Previous 1.19%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.52 - $34.67 $226,958 - $296,705	8,558 Added 2.89%	304,629 $8.12 Million
Q3 2024 Nov 14, 2024	BUY	$17.4 - $31.47 $316,262 - $571,998	18,176 Added 6.54%	296,071 $8.44 Million
Q2 2024 Aug 14, 2024	SELL	$18.84 - $24.94 $1.69 Million - $2.23 Million	-89,513 Reduced 24.36%	277,895 $6.05 Million
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $185,151 - $259,375	10,252 Added 2.87%	367,408 $8.14 Million
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $1.62 Million - $2.97 Million	132,564 Added 59.02%	357,156 $7.71 Million
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $1.02 Million - $1.55 Million	76,590 Added 51.75%	224,592 $3.79 Million
Q2 2023 Aug 11, 2023	BUY	$11.66 - $26.0 $1.73 Million - $3.85 Million	148,002 New	148,002 $2.03 Million
Q1 2021 May 14, 2021	SELL	$58.92 - $97.33 $1.35 Million - $2.22 Million	-22,831 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$43.6 - $73.05 $312,699 - $523,914	-7,172 Reduced 23.9%	22,831 $1.53 Million
Q3 2020 Nov 13, 2020	BUY	$38.47 - $52.03 $192,465 - $260,306	5,003 Added 20.01%	30,003 $1.54 Million
Q2 2020 Aug 13, 2020	BUY	$27.28 - $43.01 $682,000 - $1.08 Million	25,000 New	25,000 $942,000

Others Institutions Holding CSTL

# of Institutions

210

Shares Held

26.6M

Call Options Held

128K

Put Options Held

35.4K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $561M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.

Account

Parkman Healthcare Partners LLC Castle Biosciences Inc Transaction History